Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-05-24
|
Pennvax®-GP |
HIV infection |
1 |
Inovio Pharmaceuticals (USA - PA) |
Infectious diseases |
2017-05-23
|
Ingrezza® (valbenazine - NBI-98854) |
Tourette syndrome |
2 |
Neurocrine Biosciences (USA - CA) |
Rare diseases - Neurological diseases |
2017-05-23
|
revefenacin (TD-4208) |
chronic obstructive pulmonary disease (COPD) |
|
Mylan (USA - PA) Theravance (UK) |
Lung diseases - Respiratory diseases |
2017-05-22
|
Nucala® (mepolizumab) |
asthma |
3b |
GSK (UK) |
Inflammatory diseases - Respiratory diseases |
2017-05-22
|
BGB324 in combination with pembrolizumab or dabrafenib+trametinib |
melanoma |
1-2 |
BergenBio (Norway) |
Cancer - Oncology |
2017-05-22
|
imeglimin |
type 2 diabetes |
1 |
Poxel (France) |
Metabolic diseases |
2017-05-22
|
benralizumab |
asthma |
3 |
AstraZeneca (UK) |
Allergic diseases – Inflammatory diseases – Respiratory diseases |
2017-05-19
|
Betalutin™ (177Lu-Dota-tetulomab) |
relapsed CD37 positive non-Hodgkin lymphoma |
1-2 |
Nordic Nanovector (Norway) |
Cancer - Oncology |
2017-05-19
|
ADCT-502 |
solid tumors with HER2 expression |
1 |
ADC Therapeutics (Switzerland) |
Cancer - Oncology |
2017-05-19
|
dusquetide (SGX942) |
oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer |
2 |
Soligenix (USA - NJ) |
Cancer - Oncology |
2017-05-18
|
CEA-TCB (RO6958688; RG7802) |
carcinoembryonic antigen (CEA)-positive solid tumours, including microsatellite stable (MSS) metastatic colorectal cancers (mCRC) that overexpress CEA and progressed after at least two prior chemotherapy regimens |
1 |
Roche (Switzerland) |
Cancer - Oncology |
2017-05-18
|
SHP647 (PF-00547659) |
ulcerative colitis |
2 |
Shire (UK - USA) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-05-18
|
Ingrezza® (valbenazine - NBI-98854) |
tardive dyskinesia |
3 |
Neurocrine Biosciences (USA - CA) |
Neurological diseases |
2017-05-18
|
VXM01 |
glioblastoma |
1 |
Vaximm (Germany) |
Cancer - Oncology |
2017-05-18
|
A4250 ((2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid) |
progressive familial intrahepatic cholestasis (PFIC) |
3 |
Albireo Pharma (USA - MA) |
Rare diseases - Genetic diseases - Liver diseases - Hepatic diseases |
2017-05-17
|
mepolizumab |
eosinophilic granulomatosis with polyangiitis (EGPA) previously known as Churg-Strauss syndrome |
3 |
GSK (UK) |
Rare diseases |
2017-05-17
|
MCLA-128 |
solid tumors, breast cancer, gastric cancer, ovarian cancer, endometrial cancer, non small cell lung cancer |
1-2 |
Merus (The Netherlands) |
Cancer - Oncology |
2017-05-17
|
sarizotan |
Rett syndrome |
2 |
Newron (Italy) |
Rare diseases - Neurodevelopmental diseases |
2017-05-17
|
AUT00206 |
schizophrenia |
1b |
Autifony Therapeutics (UK) |
CNS diseases - Mental diseases |
2017-05-17
|
CX-072 in combination with Yervoy® (ipilimumab) or Zelboraf®(vemurafenib) |
solid tumors, lymphoma |
1-2 |
CytomX Therapeutics (USA - CA) |
Cancer - Oncology |